Publications by authors named "A Egeberg"
Post-Marketing Safety of Ustekinumab Based on 14-Year Follow-Up in Danish National Patient Data.
Pharmacoepidemiol Drug Saf
December 2024
Article Synopsis
- This 14-year cohort study investigated the long-term safety of ustekinumab, a biologic treatment for psoriasis, using data from Danish national registers.
- The study compared safety outcomes like cancers and serious infections in ustekinumab users against patients receiving other systemic treatments, including non-biologics and various biologic therapies.
- Results showed that ustekinumab is generally safe, with no major safety concerns identified, and users were younger and had different gender distributions compared to users of other treatments.